Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 P.m. EDT
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 P.m. EDT
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General and Special Meeting of Shareholders (the "AGM") will be webcast on June 26, 2024, at 4:30 p.m. EDT.
安大略省多倫多--(Newsfile公司-2024年6月25日)-心肌治療公司(Cardiol Therapeutics Inc.)(Cardiol已經獲得美國FDA的新藥申請授權,以評估CardiolRx在兩種影響心臟的疾病治療中的療效和安全性:(i)複發性心包炎(MAvERIC-Pilot研究;NCT05494788),心包囊的炎性疾病,伴隨有令人痛苦的胸痛、呼吸急促和疲勞的症狀,導致身體的限制、生活質量降低、急診就醫和住院入院;(ii)急性心肌炎的多國、隨機、雙盲、安慰劑對照試驗(ARCHER試驗;NCT05180240),是年輕成年人急性和暴發性心力衰竭的重要原因,也是35歲以下人群猝死的主要原因。美國FDA已授予CardiolRx孤兒藥物指定,用於治療包括複發性心包炎在內的心包炎。) (Cardiol還開發了CRD-38,一種新型皮下給藥的藥物製劑,旨在治療心衰——在發達國家是導致死亡和住院的主要原因,與美國的醫療保健費用超過300億美元相關。) ("Cardiol"或"公司一家專注於研究和臨床開發抗炎症和抗纖維化治療心臟疾病的臨床階段生命科學公司,宣佈公司的虛擬年度股東大會和特別股東大會(AGM)將於2024年6月26日東部時間下午4:30舉行。
Cardiol Therapeutics 2024 AGM
Cardiol Therapeutics 2024年股東大會
When: June 26, 2024, at 4:30 p.m. EDT
Where: Virtual meeting only via live audio webcast online at: web.lumiagm.com/253136217
時間: 2024年6月26日下午4點30分(美國東部夏令時)
地點: 只通過網絡在線音頻網絡直播參加: web.lumiagm.com/253136217
Additional information on the AGM, including details on how to participate and vote, is available on the Company's website at cardiolrx.com/investors/events-presentations/.
有關股東大會的其他信息,包括如何參加和投票的詳細信息,請訪問公司網站cardiolrx.com/investors/events-presentations/。
About Cardiol Therapeutics
關於Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
Cardiol Therapeutics Inc.(NASDAQ: CRDL,TSX: CRDL)是一家臨床生命科學公司,專注於心髒病的抗炎和抗纖維化療法的研究和臨床開發。該公司的主導小分子藥物候選者CardiolRx(大麻二酚)口服溶液,通過製藥生產並處於治療心臟病的臨床開發中。人們認識到,大麻二酚抑制炎症小體通路的激活,這是細胞內過程的一部分,已知在心肌炎、心包炎和心力衰竭伴隨的炎症和纖維化的發展和進展中發揮重要作用。Cardiol已經獲得美國FDA的新藥申請授權,以評估CardiolRx在兩種影響心臟的疾病治療中的療效和安全性:(i)複發性心包炎(MAvERIC-Pilot研究;NCT05494788),心包囊的炎性疾病,伴隨有令人痛苦的胸痛、呼吸急促和疲勞的症狀,導致身體的限制、生活質量降低、急診就醫和住院入院;(ii)急性心肌炎的多國、隨機、雙盲、安慰劑對照試驗(ARCHER試驗;NCT05180240),是年輕成年人急性和暴發性心力衰竭的重要原因,也是35歲以下人群猝死的主要原因。美國FDA已授予CardiolRx孤兒藥物指定,用於治療包括複發性心包炎在內的心包炎。) (Cardiol還開發了CRD-38,一種新型皮下給藥的藥物製劑,旨在治療心衰——在發達國家是導致死亡和住院的主要原因,與美國的醫療保健費用超過300億美元相關。有關Cardiol Therapeutics的更多信息,請訪問cardiolrx.com。
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ("US FDA") to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study; NCT05494788), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations; and (ii) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial; NCT05180240) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx for the treatment of pericarditis, which includes recurrent pericarditis.
有關前瞻性信息的警示聲明:本新聞稿包含適用證券法的“前瞻性信息”。Cardiol相信、期待或預計將來所有針對Cardiol認爲、期望或預期可能出現的活動、事件或發展的所有陳述,除歷史事實陳述外,均屬於“前瞻性信息”。 此處所含的前瞻性信息可能包括但不限於以下表述: 本公司專注於開發用於心臟病的抗炎和抗纖維化療法,本公司產品候選者的分子靶點和作用機制, 本公司擬開展的臨床研究和試驗活動及相關活動的時間表,包括評估主要療效終點和次要終點的時間表,本公司推進CRD-38的發展計劃,CRD-38是一種皮下給藥的大麻二酚新型製劑,用於心力衰竭治療,本公司期待MAvERIC-Pilot數據的整體性將支持推進CardiolRx的III期試驗。 此處所包含的前瞻性信息反映了Cardiol目前基於當前可獲得的信息的期望或信念,並基於一定的假設,也受到各種已知和未知的風險與不確定性和其他因素的影響,這些風險與不確定性和其他因素可能導致實際事件或結果與前瞻性信息所反映的任何未來結果、表現或成就有所不同,並且不(也不應該被視爲)保證未來表現。這些風險、不確定性和其他因素包括本公司在2024年4月1日向美國證券交易委員會和加拿大證券監管機構提交的20-F年度報告所提到的風險和不確定性,以及與產品商業化和臨床研究有關的風險和不確定性。此外,決定進行III期試驗的決定取決於完整的II期MAvERIC-Pilot研究結果和監管機構的授權。該研究的數據並不一定代表未來可能進行的III期研究的結果。投資者應該仔細考慮這些假設、風險、不確定性和其他因素,不應過分依賴前瞻性信息,這些信息可能不適合其他目的。任何前瞻性信息僅在本新聞稿的發佈日期發表,除非適用證券法規定,Cardiol否認對更新或修訂此類前瞻性信息的任何意向或義務,無論是基於新信息、未來事件還是結果,還是其他因素。
Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure - a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
Trevor Burns,投資者關係,+1-289-910-0855 ,trevor.burns@cardiolrx.com
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
請訪問cardiolrx.com獲取有關Cardiol Therapeutics的更多信息。
Cautionary statement regarding forward-looking information:
關於前瞻性信息的警示聲明:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to, statements relating to the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the molecular targets and mechanism of action of the Company's product candidates, the Company's intended clinical studies and trial activities and timelines associated with such activities, including for primary efficacy endpoint and secondary endpoints, and the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on April 1, 2024, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise.
本新聞稿包含適用證券法的“前瞻性信息”。所有關於Cardiol相信、期望或預計將來可能、可能、或可能發生的活動、事件或發展的聲明,除了歷史事實的陳述之外,都屬於“前瞻性信息”。本文中所包含的前瞻性信息可能包括但不限於公司專注於開發抗炎和抗纖維化療法用於治療心臟疾病、公司的產品候選的分子靶點和作用機制,公司擬進行的臨床研究和試驗活動以及相關活動的時間表,包括主要療效終點和次要終點,以及公司計劃推進CRD-38的開發,CRD-38是一種新型皮下注射用的大麻二酚製劑,用於心衰治療。前瞻性信息所反映的是Cardiol目前根據其當前可獲得的信息制定的預期或信念,基於某些假設,也將受到各種已知和未知風險和不確定性和其他因素的影響,這些因素可能導致實際事件或結果與前瞻性信息所述未來結果、表現或成就之間存在重大的差異,這些並非(也不應被視爲)未來業績的保證。這些風險和不確定性和其他因素包括公司2024年4月1日提交給美國證券交易委員會和加拿大證券監管機構的20-F表格中提到的風險和不確定性,以及與產品商業化和臨床研究相關的風險和不確定性。這些假設、風險、不確定性和其他因素應仔細考慮,投資者不應過度依賴前瞻性信息,此類信息可能不適用於其他用途。任何前瞻性信息僅在本新聞發佈之日有效,並且除適用證券法規定的情況外,Cardiol否認更新或修訂此類前瞻性信息的任何意圖或義務,不論是基於新信息、未來事件或結果還是其他任何原因。
For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com
如需更多信息,請聯繫:
投資者關係 Trevor Burns +1-289-910-0855 trevor.burns@cardiolrx.com
投資者關係 Trevor Burns +1-289-910-0855 trevor.burns@cardiolrx.com